#For patients
Written for adults considering a peptide as part of their health management.
Tirzepatide and Work: Survey Findings
A survey of 518 US employees starting tirzepatide found strong support for obesity-drug coverage, but it did not measure treatment effects.
Tirzepatide and Exercise Anaphylaxis
A case report links tirzepatide with exercise-induced anaphylaxis in one patient, with no recurrence after the medicine was stopped.
GLP-1 Drugs and Skin Disease Evidence
A 2026 review finds the strongest GLP-1 skin evidence in psoriasis, while most other dermatology uses remain observational.
Do GLP-1 Drugs Affect Muscle and Bone?
A 2026 meta-analysis found a low-certainty lean-mass signal with GLP-1 drugs, but no adjusted effect on bone or joint outcomes.
Knee Surgery: Semaglutide vs Tirzepatide
A matched US study found similar short-term knee-replacement outcomes in people with diabetes prescribed semaglutide or tirzepatide.
Semaglutide pregnancy case series
A 2026 case series reported outcomes after first-trimester semaglutide exposure in 16 pregnancies. The result is useful but cannot establish safety.
Tirzepatide anhedonia: three case reports
Three patients reported improved motivation after tirzepatide dose reduction, but the uncontrolled case series cannot establish frequency or causation.
Semaglutide neuropathy case report
A single case found improved corneal nerve measurements after semaglutide, while neuropathy symptoms and disability scores stayed unchanged.
Tesamorelin cost in the Netherlands
Tesamorelin has no EMA authorisation after the 2012 withdrawal. No GVS listing, no official Dutch price, no ZVW cover exists. Here is the full picture for 2026.
GLP-1 Drugs and Anesthesia Safety
A 2026 study compared anesthesia outcomes for lipoabdominoplasty patients taking semaglutide or tirzepatide against those who were not.
Is a 'research use only' peptide legal?
A research use only label on a peptide vial does not answer whether a clinic can legally give it to a patient.
Semaglutide and Alzheimer's after EVOKE
Semaglutide failed both EVOKE Alzheimer's trials. A new paper argues research should shift from one hypothesis to a stratified program.